Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Idec Says Tysabri Patient Counts Are On The Upswing

This article was originally published in The Pink Sheet Daily

Executive Summary

But economy and competitive MS market could provide headwinds going forward.

You may also be interested in...



Biogen Idec/Acorda Strike Licensing Deal For MS Candidate Fampridine-SR

Biogen gains revenues, Acorda gets a strong partner well-entrenched in the EU MS market.

Biogen Idec/Acorda Strike Licensing Deal For MS Candidate Fampridine-SR

Biogen gains revenues, Acorda gets a strong partner well-entrenched in the EU MS market.

As Rumors About A Potential Acquisition Fly, Elan Names Two Dissidents To Its Board

Avoiding a proxy fight, the Irish firm placed two hostile members on its board, likely spelling trouble for CEO Martin.

Related Content

Topics

UsernamePublicRestriction

Register

PS069291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel